oral tirzepatide vs injectable tirzepatide: what actually exists, what does not, and what is coming next Choosing Between Tirzepatide and Semaglutide

Further increases to 1 mg or 2 mg weekly should only occur if tolerated and if additional glycaemic control is needed, following the UK SmPC recommendations

Novo Nordisk: Patenting Activity Novo Nordisks patent filing activity surged in 2017, coinciding with the U.S

This GLP-1 agonism leads to a direct impact on the hypothalamus, the brains hunger center, signaling fullness and reducing the urge to eat

Accessed 1/5/2024, Wuopio J, Ling YT, Orho-Melander M, Engstrom G, Arnlov J

Each compound targets different tissues, different receptors, and different metabolic processes

This will inevitably keep the preventative use of GLP-1 agonists off label for a long time if not forever